News Lobby groups call for closure of “revolving door” between drug regulators and industry BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d8335 (Published 30 December 2011) Cite this as: BMJ 2011;343:d8335 Article Related content Metrics Responses Peer review Related articles No related articles found. See more Cancer drugs remain FDA approved despite lack of benefit, study finds BMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568 Johnson & Johnson is ordered to pay $1bn over faulty hip implants BMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Trial of novel leukaemia drug is stopped for second time after two more deaths BMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376 Promise of new Alzheimer’s drug is dashed after lack of evidence BMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362 Cited by... Revolving doors and conflicts of interest in health regulatory agencies in BrazilFulltext PDF
